{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:32:28Z","timestamp":1789842748942,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg Cases"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Preoperative nivolumab combination chemotherapy has shown its efficacy in resectable stage II\u2013III non-small cell lung cancer and become one of the standard treatments. While preoperative nivolumab combination chemotherapy is generally a regimen of three cycles, the efficacy of nivolumab combination chemotherapy when treatment is prematurely discontinued remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>An 81-year-old man was diagnosed as lung adenocarcinoma (cT3N1M0, cStage IIIA). A computed tomography (CT) showed a 58 mm mass in left upper lobe with an intrapulmonary metastasis, and a positron-emission tomography\/CT suggested metastatic lymph nodes at the left pulmonary hilum. Preoperative nivolumab\u2009+\u2009carboplatin\u2009+\u2009paclitaxel were administered; however, after the first cycle, the treatment was discontinued due to grade 3 anorexia, grade 1 body weight loss, and grade 4 neutropenia. It was affair that continuation of preoperative therapy made him unsuitable for surgery, and CT scan showed a reduction in the tumor size to 20 mm. Then, we decided to discontinue the preoperative therapy and perform surgery. Video-assisted thoracoscopic left upper lobectomy and lymph node dissection were performed, and the postoperative course was uneventful. The pathological examination revealed 15% of residual tumor cell in primary lesion and no metastatic lymph nodes was diagnosed. The patient did not undergo adjuvant chemotherapy, and no recurrence was observed 1.5 years after surgery<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this case, preoperative nivolumab combined chemotherapy was discontinued only one cycle due to adverse events; however, a significant treatment effect was achieved. Therefore, even it is unable to continue preoperative nivolumab combined therapy, it is important not to miss the chance of surgery, as good treatment effect may have been achieved.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s44215-025-00187-5","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:05:56Z","timestamp":1738598756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A stage IIIA lung adenocarcinoma case achieving pathological response with only one cycle of preoperative nivolumab combination chemotherapy"],"prefix":"10.1186","volume":"4","author":[{"given":"Shuhei","family":"Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-0491","authenticated-orcid":false,"given":"Fumihiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"187_CR1","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med"},{"key":"187_CR2","doi-asserted-by":"publisher","unstructured":"Cornelissen R, Havel L, Karaseva N, et al. Perioperative nivolumab in resectable lung cancer. Epub ahead of print 2024. https:\/\/doi.org\/10.1056\/NEJMoa2311926.","DOI":"10.1056\/NEJMoa2311926"},{"key":"187_CR3","doi-asserted-by":"crossref","unstructured":"Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N Engl J Med. 2023;389:491\u2013503.","DOI":"10.1056\/NEJMoa2302983"},{"key":"187_CR4","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non\u2013small-cell lung cancer. N Engl J Med. 2023;389:1672\u201384.","journal-title":"N Engl J Med"},{"key":"187_CR5","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/cncr.34755","volume":"129","author":"Y Wu","year":"2023","unstructured":"Wu Y, Verma V, Gay CM, et al. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: a systematic review and meta-analysis. Cancer. 2023;129:1969\u201385.","journal-title":"Cancer"},{"key":"187_CR6","doi-asserted-by":"crossref","unstructured":"Banna GL, Hassan MA, Signori A, et al. Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:e246837.","DOI":"10.1001\/jamanetworkopen.2024.6837"},{"key":"187_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","volume":"20","author":"G Mountzios","year":"2023","unstructured":"Mountzios G, Remon J, Hendriks LEL, et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023;20:664\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"187_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107314","volume":"183","author":"MR Conroy","year":"2023","unstructured":"Conroy MR, Dennehy C, Forde PM. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer. Lung Cancer. 2023;183: 107314.","journal-title":"Lung Cancer"},{"key":"187_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/jamaoncol.2022.5389","volume":"9","author":"AP Desai","year":"2023","unstructured":"Desai AP, Adashek JJ, Reuss JE, et al. Perioperative immune checkpoint inhibition in early-stage non-small cell lung cancer: a review. JAMA Oncol. 2023;9:135\u201342.","journal-title":"JAMA Oncol"},{"key":"187_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch JS, Cimino-Mathews A, Thompson E, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30:218\u201328.","journal-title":"Nat Med"},{"key":"187_CR11","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976\u201386.","journal-title":"N Engl J Med"},{"key":"187_CR12","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/JCO.2023.41.16_suppl.8509","volume":"41","author":"K Aokage","year":"2023","unstructured":"Aokage K, Shimada Y, Yoh K, et al. Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY). J Clin Oncol. 2023;41:8509.","journal-title":"J Clin Oncol"},{"key":"187_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-019-0413-5","volume":"39","author":"H Kimura","year":"2019","unstructured":"Kimura H, Araya T, Yoneda T, et al. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun. 2019;39:1\u20135.","journal-title":"Cancer Commun"},{"key":"187_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4819-2","volume":"18","author":"M Tachihara","year":"2018","unstructured":"Tachihara M, Negoro S, Inoue T, et al. Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer. 2018;18:1\u20136.","journal-title":"BMC Cancer"}],"container-title":["General Thoracic and Cardiovascular Surgery Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44215-025-00187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44215-025-00187-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44215-025-00187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:06:00Z","timestamp":1738598760000},"score":1,"resource":{"primary":{"URL":"https:\/\/gtcscases.biomedcentral.com\/articles\/10.1186\/s44215-025-00187-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1186\/s44215-025-00187-5","relation":{},"ISSN":["2731-6203"],"issn-type":[{"value":"2731-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent to the patient in this case report has been obtained from the patient himself.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication has been obtained from the patient himself.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}